News
AZ announces US fast track designation for IL-5 inhibitor Fasenra
AstraZeneca’s IL-5 inhibitor Fasenra (benralizumab) has received a fast-track designation from the US Food and Drug Administration for the treatment of eosinophilic gastritis (EG), with or without eosinophilic gastroenteritis (EGE).